Point mutations in the FLT3 gene in AML.
Griffin
J D
JD
Dana-Farber Cancer Institute.
D000208:Acute Disease; D019943:Amino Acid Substitution; D001216:Asparagine / Q000737:chemistry; D003062:Codon / Q000235:genetics; D004789:Enzyme Activation; D006801:Humans; D007951:Leukemia, Myeloid / Q000201:enzymology / Q000235:genetics*; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000737:chemistry / Q000235:genetics*; D010766:Phosphorylation; D017354:Point Mutation; D011487:Protein Conformation; D011499:Protein Processing, Post-Translational; D011518:Proto-Oncogene Proteins / Q000737:chemistry / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases / Q000737:chemistry / Q000235:genetics*; D013329:Structure-Activity Relationship; D051941:fms-Like Tyrosine Kinase 3
D003062:Codon; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D001216:Asparagine; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3